RxDoctor Payments DataLook up a doctor →

Steven Herzog, MD

Neurology · Dallas, TXNPI 1972579449

Payments from drug & device makers

$1,350,100in general payments, 2019–2025

Across 1,277 payments — averaging $1057.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$670K
  • Neurology Practice Consortium GPO, LLC$468K
  • H. Lundbeck A S$77K
  • Ipsen Innovation$48K
  • Novartis$18K
  • Biohaven Pharmaceuticals, Inc.$16K
  • plus $52K from 54 others
$1,576in research payments, 2019–2025

Across 2 payments — averaging $788.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)608$670,162
Neurology Practice Consortium GPO, LLC7$468,226
H. Lundbeck A S32$77,371
Ipsen Innovation39$48,037
Novartis60$17,734
Biohaven Pharmaceuticals, Inc.19$16,417
Biohaven Pharmaceutical Holding Company Ltd.26$14,912
Eli Lilly2$12,910
Amgen(2 entities)29$9,834
Teva Pharmaceuticals USA, Inc.20$3,857
Lundbeck LLC39$3,553
Lilly USA, LLC29$757
Genentech USA, Inc.40$719
Sunovion Pharmaceuticals Inc.36$591
Pfizer40$559
UCB, Inc.19$356
Argenx US, Inc.15$341
Upsher-smith Laboratories LLC31$297
Biogen16$263
AstraZeneca12$232
Merz Pharmaceuticals, LLC6$225
Amneal Pharmaceuticals LLC21$221
Johnson & Johnson(2 entities)12$203
Supernus Pharmaceuticals, Inc.11$161
Takeda Pharmaceuticals U.S.A., Inc.7$152
CSL Behring6$144
SK Life Science, Inc.9$143
Neurocrine Biosciences, Inc.5$134
Acorda Therapeutics, Inc7$132
Eisai Inc.5$124
Grifols USA, LLC5$105
Merz North America, Inc.3$103
TG Therapeutics, Inc.5$94
Alnylam Pharmaceuticals Inc.4$91
Sanofi5$86
EMD Serono, Inc.5$71
Siemens Medical Solutions USA, Inc.2$64
Hospira, Inc.4$56
Tonix Medicines, Inc.2$53
Neurelis, Inc.2$46
Tanabe Pharma America, Inc.3$46
Kyowa Kirin, Inc.2$45
Acadia Pharmaceuticals Inc2$40
Vanda Pharmaceuticals Inc.1$34
Boston Scientific2$34
Promius Pharma LLC2$33
Adamas Pharmaceuticals, Inc.2$31
GE HealthCare2$30
Mallinckrodt Enterprises LLC1$28
Harmony Biosciences LLC2$24
Ipsen Biopharmaceuticals, Inc1$22
Octapharma USA, Inc.1$21
Avanir Pharmaceuticals, Inc.1$21
Scilex Pharmaceuticals Inc.1$18
Philips North America LLC1$18
Impel Pharmaceuticals LLC1$17
Assertio Therapeutics, Inc.1$17
Almatica Pharma LLC1$15
Banner Life Sciences, LLC1$15
Bristol Myers Squibb1$15

How this compares

$1,350,100 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024
$2,290,960
Medicare patients
610
Services billed
250,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →